Bläckberg M, Ohlsson K
Department of Surgical Pathophysiology, University of Lund, Malmö General Hospital, Sweden.
Scand J Clin Lab Invest. 1994 Dec;54(8):643-51. doi: 10.3109/00365519409087545.
The elimination of radio-iodinated porcine tissue kallikrein, after intravenous injection in the pig, showed a rapid initial clearance from plasma (T1/2 approximately 10 min), followed by a phase of slower elimination (T1/2 approximately 100 min). Gel filtration of plasma samples showed complexes with alpha 1-alpha 2-macroglobulin (A1a2-M) and alpha 1-proteinase inhibitor (A1-PI), which decreased with time. The urinary excretion of undegraded tissue kallikrein was about 1.8%. Gel filtration of urine showed a minor peak representing free tissue kallikrein and a major peak representing degradation products. On average, 8.3% was found in the liver and 1.3% in the kidneys post mortem, indicating that these are the primary organs for the elimination of tissue kallikrein. The in vivo findings were supported by in vitro experiments. A1a2-M were found to be the major inhibitors of tissue kallikrein, when a mixture of the enzyme and porcine plasma was analysed by gel filtration, immunoelectrophoresis, crossed immunoelectrophoresis and autoradiography. A1-PI was only a minor inhibitor of tissue kallikrein. Both the A1a2-M and A1-PI complex formation was found to be time-dependent and slow; unbound glandular kallikrein was still detected after 12 h, even when there was a molar surplus of A1a2-M and A1-PI. The complexes with A1a2-M and the unbound tissue kallikrein were found to be enzymatically active against low-molecular-weight chromogenic substrate. The total tissue kallikrein-inhibiting capacity of plasma seemed to be exceeded at a concentration of 800 K U/l when analysed using the rat uterus bioassay.(ABSTRACT TRUNCATED AT 250 WORDS)
给猪静脉注射放射性碘化猪组织激肽释放酶后,其消除情况显示,最初血浆清除迅速(半衰期约10分钟),随后是消除较慢的阶段(半衰期约100分钟)。血浆样本的凝胶过滤显示与α1-α2-巨球蛋白(A1a2-M)和α1-蛋白酶抑制剂(A1-PI)形成复合物,且复合物随时间减少。未降解组织激肽释放酶的尿排泄量约为1.8%。尿液的凝胶过滤显示一个代表游离组织激肽释放酶的小峰和一个代表降解产物的大峰。死后平均在肝脏中发现8.3%,在肾脏中发现1.3%,表明这些是消除组织激肽释放酶的主要器官。体内研究结果得到体外实验的支持。当通过凝胶过滤、免疫电泳、交叉免疫电泳和放射自显影分析酶与猪血浆的混合物时,发现A1a2-M是组织激肽释放酶的主要抑制剂。A1-PI只是组织激肽释放酶的次要抑制剂。发现A1a2-M和A1-PI的复合物形成均具有时间依赖性且缓慢;即使A1a2-M和A1-PI存在摩尔过量,12小时后仍能检测到未结合的腺体激肽释放酶。发现与A1a2-M形成的复合物和未结合的组织激肽释放酶对低分子量显色底物具有酶活性。使用大鼠子宫生物测定法分析时,如果血浆浓度达到800KU/l,似乎会超过血浆总的组织激肽释放酶抑制能力。(摘要截短至250字)